Department of Medicine A - Gastroenterology, Nephrology, Endocrinology and Rheumatology, University Medicine Greifswald, Greifswald, Germany.
Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sci Rep. 2023 Mar 30;13(1):5230. doi: 10.1038/s41598-023-32363-4.
Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick's value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β - 0.057 g/L 95% CI - 0.073; - 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further.
高精氨酸（hArg）是一种非必需的阳离子氨基酸，通过靶向肝内胆管上皮细胞来抑制肝碱性磷酸酶，从而发挥抑制胆汁分泌的作用。我们分析了（1）在两项大型人群研究中 hArg 与肝生物标志物之间的关系，以及（2）hArg 补充对肝生物标志物的影响。我们在适当调整的线性回归模型中评估了丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、γ-谷氨酰转移酶（GGT）、碱性磷酸酶（AP）、白蛋白、总胆红素、胆碱酯酶、Quick 值、肝脂肪和终末期肝病模型（MELD）与 hArg 之间的关系。我们分析了 L-hArg 补充（每天 125mg L-hArg，持续 4 周）对这些肝生物标志物的影响。我们纳入了 7638 名个体（男性：3705 名；绝经前女性：1866 名，绝经后女性：2067 名）。我们发现 hArg 与 ALT（β 0.38 µkatal/L 95%置信区间（CI）：0.29；0.48）、AST（β 0.29 µkatal/L 95% CI 0.17；0.41）、GGT（β 0.033 µkatal/L 95% CI 0.014；0.053）、Fib-4 评分（β 0.08 95% CI 0.03；0.13）、肝脂肪含量（β 0.016% 95% CI 0.006；0.026）、白蛋白（β 0.030 g/L 95% CI 0.019；0.040）和胆碱酯酶（β 0.003 µkatal/L 95% CI 0.002；0.004）呈正相关。在绝经前女性中，hArg 与肝脂肪含量呈正相关（β 0.047% 95%CI 0.013；0.080），与白蛋白呈负相关（β -0.057 g/L 95% CI -0.073；-0.041）。绝经后女性的 hARG 与 AST（β 0.26 µkatal/L 95% CI 0.11；0.42）呈正相关。hArg 补充剂对肝生物标志物没有影响。我们总结认为，hArg 可能是肝功能障碍的标志物，应进一步探索。
